# US 2006/0078574 A1 · Purified phospholipid-non-steroidal anti-inflammatory drug associated compositions and methods for preparing and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0078574 A1
- Document ID: US20060078574A1
- Status: Published application
- Kind: A1
- Application number: 11/249,051
- Filed: 2005-10-12
- Published: 2006-04-13
- Earliest claimed: 2004-10-12
- Assignees: Board of Regents, The University of Texas System
- Inventors: Lenard Lichtenberger
- Web page: https://patentgrep.com/patent/US20060078574A1

## CPC

- A61K 31/683: Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 31/60: Salicylic acid; Derivatives thereof
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 31/688: both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A new pharmaceutical composition is disclosed comprising a purified phospholipid-selective and/for nonselective non-steroidal, anti-inflammatory drug associated complex and methods for making and using same. A screening method for identifying compounds that form phospholipid associated complexes is also disclosed.

## Claims

### Claim 1

A method comprising the step of:
contacting one selective or nonselective non-steroidal, anti-inflammatory drug (sns-NSAID) or a plurality of sns-NSAIDs and one phospholipid (PL) or a plurality of PLs in a polar solvent under conditions adapted to produce a solution including purified PL-sns-NSAID associated complexes; and
removing the solvent below a desired level to form a composition comprising purified PL-sns-NSAID associated complexes.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sns-NSAIDs are selected from the group consisting of non-steroidal, anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors.

### Claim 3 (depends on 2)

The method of claim 2, wherein the NSAIDs are selected from the group consisting of Fenoprofen calcium (Nalfon®), Flurbiprofen (Ansaid®), Suprofen. Benoxaprofen, Ibuprofen (Motrin®, Advil®), Ketoprofen (Orduis, Oruvall®), Naproxen (Naprosyn®), Naproxen sodium (Aleve®, Anaprox®, Aflaxen®), Oxaprozin (Daypro®), Diclofenac sodium (Voltaren®), Diclofenac potassium (Cataflam®), Etodolac (Lodine®), Indomethacin (Indocin®), Ketorolac tromethamine (Acular, Toradol® intramuscular), Ketorolac (oral Toradol®), Nabumetone (Relafen®), Sulindac (Clinoril®), Tolmetin sodium (Tolectin®), Meclofenamate sodium (Meclomen®), Mefenamic acid (Ponstel®), Piroxicam (Dolibid®),Diflunisal (Feldene®), Aspirin, Oxyphenbutazone (Tandearil®), Phenylbutazone (Butazolidin®), acetaminophen (Tylenol®), and mixtures or combinations thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein the NSAIDs are selected from the group consisting of ibuprofen, aspirin, salicylic acid, naproxen, indomethacin, diclofenac, piroxicam, fluobiprofen, ketoprofen and mixtures or combinations thereof.

### Claim 5 (depends on 2)

The method of claim 2, wherein the COX-2 inhibitors are selected from the group consisting of celecoxib, lumiracoxib, meloxicam, meloxicam, piroxicam, or newly approved COX-2 inhibitors or mixtures or combinations thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the phospholipid is one or more compounds of the general formula:
where R1 and R2 are saturated or unsaturated substitutions ranging from 8 to 32 carbon atoms; R3 is H or CH3, and X is H or COOH; and R4 is ═O or H2.

### Claim 7 (depends on 1)

The method of claim 1, wherein the phospholipid is phosphatidylcholine selected from the group consisting of phosphatidylcholine (PC), dipalmitoylphosphatidylcholine (DPPC), other disaturated phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositol, phosphatidyl serines sphingomyelin or other ceramides, lecithin oils derived from soy beans, dimyristoyl phosphatidylcholine, distearoylphosphatidylcholine, dilinoleoylphosphatidylcholine (DLL-PC), dipalmitoylphosphatidylcholine (DPPC), soy phophatidylchloine (Soy-PC or PCS), egg phosphatidycholine (Egg-PC or PCE) and mixtures or combinations thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the solvent is selected from the group consisting of acetone, methylethyl ketone (MEK), methylbutyl ketone, methylisobutyl ketone or the like, acetates such as methylacetate, ethylacetate, propylacetate, isopropyl acetate, butylacetate, isobutylacetate, or the like, nitriles such as acetonitrile or the like, ethers such as diethylether, tetrahydrofuran, or the like, formates such as ethylformate, N,N-dimethylacetamide, N,N-dimethylformamide, N-methylpyrrolidone, nitromethane, chlorinated hydrocarbons such as carbon tetrachloride, chloroform, 1,2-dichloroethane, 1,1-dichlorethene, 1,2-dichloroethene, dichloromethane, 1,1,1-trichloroethane or the like, or mixture or combinations thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the desired level is at or below an FDA approved level or at or below a detection limit of the solvent.

### Claim 10 (depends on 1)

The method of claim 1, wherein the solvent is acetone.

### Claim 11

A method comprising the steps of:
administering a therapeutically effective amount of a composition to an animal including a human,
where the composition is prepared by a method comprising the steps of:
contacting one selective or nonselective non-steroidal, anti-inflammatory drug (sns-NSAID) or a plurality of sns-NSAIDs and one phospholipid (PL) or a plurality of PLs in a polar solvent under conditions adapted to produce a solution including PL-sns-NSAID associated complexes; and
removing the solvent to a desired level to form a composition comprising purified PL-sns-NSAID associated complexes.

### Claim 12 (depends on 11)

The method of claim 11, wherein the composition preparing method further comprising the step of:
prior to the removing step, cooling the solution for a cooling time and at a cooling temperature, where the cooling time and cooling temperature are sufficient to precipitate any PL not associated with the sns-NSAID or any PL in excess of an associated amount, and
separating any precipitate to produce the solution.

### Claim 13 (depends on 11)

The method of claim 11, wherein the administering step is selected from the group consisting of an oral administering step, an enteral administering step, a rectal administering step, a topical administering step, an intravenous administering step for sterile preparations, an intra-arterial administering step for sterile preparations, an intramuscular administering step for sterile preparations, a direct tissue injection administering step for sterile preparations, a sub-dermal pump administering step for sterile preparations or a nasal administering step.

### Claim 14 (depends on 11)

The method of claim 11, wherein the sns-NSAIDs are selected from the group consisting of non-steroidal, anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors.

### Claim 15 (depends on 14)

The method of claim 14, wherein the NSAIDs are selected from the group consisting of Fenoprofen calcium (Nalfon®), Flurbiprofen (Ansaid®), Suprofen. Benoxaprofen, Ibuprofen (Motrin®, Advil®), Ketoprofen (Orduis, Oruvall®), Naproxen (Naprosyn®), Naproxen sodium (Aleve®, Anaprox®, Aflaxen®), Oxaprozin (Daypro®), Diclofenac sodium (Voltaren®), Diclofenac potassium (Cataflam®), Etodolac (Lodine®), Indomethacin (Indocin®), Ketorolac tromethamine (Acular, Toradol® intramuscular), Ketorolac (oral Toradol®), Nabumetone (Relafen®), Sulindac (Clinoril®), Tolmetin sodium (Tolectin®), Meclofenamate sodium (Meclomen®), Mefenamic acid (Ponstel®), Piroxicam (Dolibid®),Diflunisal (Feldene®), Aspirin, Oxyphenbutazone (Tandearil®), Phenylbutazone (Butazolidin®), acetaminophen (Tylenol®), and mixtures or combinations thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the NSAIDs are selected from the group consisting of ibuprofen, aspirin, salicylic acid, naproxen, indomethacin, diclofenac, piroxicam, fluobiprofen, ketoprofen and mixtures or combinations thereof.

### Claim 17 (depends on 14)

The method of claim 14, wherein the COX-2 inhibitors are selected from the group consisting of celecoxib, lumiracoxib, meloxicam, meloxicam, piroxicam, or newly approved COX-2 inhibitors or mixtures or combinations thereof

### Claim 18 (depends on 11)

The method of claim 11, wherein the phospholipid is one or more compounds of the general formula:
where R1 and R2 are saturated or unsaturated substitutions ranging from 8 to 32 carbon atoms; R3 is H or CH3, and X is H or COOH; and R4 is ═O or H2.

### Claim 19 (depends on 11)

The method of claim 11, wherein the phospholipid is phosphatidylcholine selected from the group consisting of phosphatidylcholine (PC), dipalmitoylphosphatidylcholine (DPPC), other disaturated phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositol, phosphatidyl serines sphingomyelin or other ceramides, lecithin oils derived from soy beans, dimyristoyl phosphatidylcholine, distearoylphosphatidylcholine, dilinoleoylphosphatidylcholine (DLL-PC), dipalmitoylphosphatidylcholine (DPPC), soy phophatidylchloine (Soy-PC or PCS), egg phosphatidycholine (Egg-PC or PCE) and mixtures or combinations thereof.

### Claim 20 (depends on 11)

The method of claim 11, wherein the solvent is selected from the group consisting of acetone, methylethyl ketone (MEK), methylbutyl ketone, methylisobutyl ketone or the like, acetates such as methylacetate, ethylacetate, propylacetate, isopropyl acetate, butylacetate, isobutylacetate, or the like, nitriles such as acetonitrile or the like, ethers such as diethylether, tetrahydrofuran, or the like, formates such as ethylformate, N,N-dimethylacetamide, N,N-dimethylformamide, N-methylpyrrolidone, nitromethane, chlorinated hydrocarbons such as carbon tetrachloride, chloroform, 1,2-dichloroethane, 1,1-dichlorethene, 1,2-dichloroethene, dichloromethane, 1,1,1-trichloroethane or the like, or mixture or combinations thereof.

### Claim 21 (depends on 11)

The method of claim 11, wherein the desired level is at or below an FDA approved level or at or below a detection limit of the solvent.

### Claim 22 (depends on 11)

The method of claim 11, wherein the solvent is acetone.

### Claim 23

A composition comprising purified associated complexes of one phospholipid (PL) or a plurality of PLs and one selective or nonselective non-steroidal, anti-inflammatory drug (sns-NSAID) or a plurality of sns-NSAIDs having a weight ratio of sns-NSAIDs to PLs where the sns-NSAID is present in an amount sufficient to prevent precipitation of the PLs when the composition is dissolved in a polar solvent in which the PL has moderate, low or no solubility.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the sns-NSAIDs are selected from the group consisting of non-steroidal, anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors.

### Claim 25 (depends on 24)

The composition of claim 24, wherein the NSAIDs are selected from the group consisting of Fenoprofen calcium (Nalfon®), Flurbiprofen (Ansaid®), Suprofen. Benoxaprofen, Ibuprofen (Motrin®, Advil®), Ketoprofen (Orduis, Oruvall®), Naproxen (Naprosyn®), Naproxen sodium (Aleve®, Anaprox®, Aflaxen®), Oxaprozin (Daypro®), Diclofenac sodium (Voltaren®), Diclofenac potassium (Cataflam®), Etodolac (Lodine®), Indomethacin (Indocin®), Ketorolac tromethamine (Acular, Toradol® intramuscular), Ketorolac (oral Toradol®), Nabumetone (Relafen®), Sulindac (Clinoril®), Tolmetin sodium (Tolectin®), Meclofenamate sodium (Meclomen®), Mefenamic acid (Ponstel®), Piroxicam (Dolibid®), Diflunisal (Feldene®), Aspirin, Oxyphenbutazone (Tandearil®), Phenylbutazone (Butazolidin®), acetaminophen (Tylenol®), and mixtures or combinations thereof.

### Claim 26 (depends on 25)

The composition of claim 25, wherein the NSAIDs are selected from the group consisting of ibuprofen, aspirin, salicylic acid, naproxen, indomethacin, diclofenac, piroxicam, fluobiprofen, ketoprofen and mixtures or combinations thereof.

### Claim 27 (depends on 24)

The composition of claim 24, wherein the COX-2 inhibitors are selected from the group consisting of celecoxib, lumiracoxib, meloxicam, meloxicam, piroxicam, or newly approved COX-2 inhibitors or mixtures or combinations thereof

### Claim 28 (depends on 23)

The composition of claim 23, wherein the phospholipids are one or more compounds of the general formula:
where R1 and R2 are saturated or unsaturated substitutions ranging from 8 to 32 carbon atoms; R3 is H or CH3, and X is H or COOH; and R4 is ═O or H2.

### Claim 29 (depends on 23)

The composition of claim 23, wherein the phospholipids are phosphatidylcholine selected from the group consisting of phosphatidylcholine (PC), dipalmitoylphosphatidylcholine (DPPC), other disaturated phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositol, phosphatidyl serines sphingomyelin or other ceramides, lecithin oils derived from soy beans, dimyristoyl phosphatidylcholine, distearoylphosphatidylcholine, dilinoleoylphosphatidylcholine (DLL-PC), dipalmitoylphosphatidylcholine (DPPC), soy phophatidylchloine (Soy-PC or PCS), egg phosphatidycholine (Egg-PC or PCE) and mixtures or combinations thereof.

### Claim 30 (depends on 23)

The composition of claim 23, wherein the solvent is selected from the group consisting of acetone, methylethyl ketone (MEK), methylbutyl ketone, methylisobutyl ketone or the like, acetates such as methylacetate, ethylacetate, propylacetate, isopropyl acetate, butylacetate, isobutylacetate, or the like, nitriles such as acetonitrile or the like, ethers such as diethylether, tetrahydrofuran, or the like, formates such as ethylformate, N,N-dimethylacetamide, N,N-dimethylformamide, N-methylpyrrolidone, nitromethane, chlorinated hydrocarbons such as carbon tetrachloride, chloroform, 1,2-dichloroethane, 1,1-dichlorethene, 1,2-dichloroethene, dichloromethane, 1,1,1-trichloroethane or the like, or mixture or combinations thereof.

### Claim 31 (depends on 23)

The composition of claim 23, wherein the solvent is acetone.

### Claim 32 (depends on 23)

The composition of claim 23, wherein the weight ratio is at least 1:2 sns-NSAID to PL.
